<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033354</url>
  </required_header>
  <id_info>
    <org_study_id>HLX10-004-NSCLC303</org_study_id>
    <nct_id>NCT04033354</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin Nanoparticle Albumin Bound (Nab)-Paclitaxel) vs Chemotherapy (Carboplatin Nab-Paclitaxel) as First-Line Therapy for Locally Advanced or Metastatic Squamous Non Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, multicenter, phase III clinical study to compare
      the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with
      locally advanced or metastatic squamous NSCLC who have not previously received systemic
      treatment.

      Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows:

      Arm A (HLX10 arm): HLX10 + chemotherapy (carboplatin nab paclitaxel) Arm B (placebo arm):
      Placebo + chemotherapy (carboplatin nab paclitaxel) The three stratification factors for
      randomization include: PD-L1 expression level (Tumor Proportion Scores [TPS]≥50%, 50%&gt;TPS≥1%,
      TPS&lt;1%), Asian population (yes or no), NSCLC stage (stage IIIB/IIIC or stage IV), and
      carboplatin AUC (5 or 6).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor assessment</measure>
    <time_frame>Baseline until disease progression or death, whichever occurs first (up to approximately 24months)</time_frame>
    <description>Progression-free survival (PFS) (assessed by the independent radiology review committee [IRRC] based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">516</enrollment>
  <condition>Squamous Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX10 + chemotherapy (carboplatin nab paclitaxel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + chemotherapy (carboplatin nab paclitaxel), After 1st PD, the subject will be unblinded by the investigator and be continued with HLX10 monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX10</intervention_name>
    <description>HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin and nab paclitaxel</intervention_name>
    <description>chemotherapeutics</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed stage IIIB/IIIC and stage IV
             (AJCC Edition 8) squamous NSCLC where surgery or radiotherapy cannot be performed.

          2. No known sensitizing EGFR mutations or ALK, ROS1 gene rearrangements.

          3. Major organs are functioning well

          4. Participant must keep contraception

          5. Patients with prior denosumab use who can agree to switch to bisphosphonate therapy
             for bone metastases in the study.

        Exclusion Criteria:

          1. Patients with histologically non-squamous NSCLC. Mixed tumors will be classified
             according to the primary cell type. Patients do not meet the requirements for
             enrollment if small cell components and neuroendocrine carcinoma components are
             present. For non-small cell histology, patients meet the requirements for enrollment
             if squamous components (e.g., adenosquamous) are present.

          2. Patients with known history of severe hypersensitivity to any monoclonal antibody.

          3. Patients with known hypersensitivity to any compositions of carboplatin or
             nab-paclitaxel.

          4. Pregnant or breastfeeding females.

          5. Patients with a known history of psychotropic drug abuse or drug addiction; or a
             history of alcohol abuse.

          6. Patients who have other factors that could lead to the early termination of this study
             based on the investigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sun Jia, Master</last_name>
    <phone>+8618660134000</phone>
    <email>Jia_Sun@henlius.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Qiong, Master</last_name>
    <phone>+8618627113916</phone>
    <email>Qiong_Wang@henlius.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Jia</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Jia, Master</last_name>
      <phone>+8618660134000</phone>
      <phone_ext>+8618660134000</phone_ext>
      <email>Jia_Sun@henlius.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wang Qiong, Master</last_name>
      <phone>+8618627113916</phone>
      <email>Qiong_Wang@henlius.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally Advanced or Metastatic</keyword>
  <keyword>Squamous Non Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

